Report Publication Announcement • Mar 21, 2016
Report Publication Announcement
Open in ViewerOpens in native device viewer
PRESS RELEASE PRESS RELEASE PRESS RELEASE
Paris, March 21, 2016 – NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, will be pleased to meet investors during:
For more details on the event:http://www.midcapevents.com/small2016/home/
__________
Financial Calendar for Neovacs: April 13th, 2016: Shareholders' AGM October 14th, 2016: 2016 Half-Year results
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. All information about Neovacs is available on the website: www.neovacs.fr
Contacts Neovacs/ Charlène Masson +33 (0)1 53 10 93 00 [email protected] New Cap /Valentine Brouchot / Pierre Laurent +33 (0)1 44 71 94 94 [email protected]
Press / U.S. Inquiries – The Ruth Group Joanna Zimmerman / Joseph Green +1-646-536-7012 / 7013 [email protected] / [email protected]
Investor Relations / Financial Communications Germany – MC Services Raimund Gabriel +49-89-21-02-28-30 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.